pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not ap
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
Quick answer
AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not applicable, healthy volunteers. NovaPharmaNews links 249 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (120), phase 2 (79), phase 1 (46).
Company snapshot
AstraZeneca maintains 249 tracked programs across Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not applicable, healthy volunteers, Chronic kidney disease (CKD) and hypertension., Metastatic Prostate Cancer, Locoregional Hepatocellular Carcinoma (HCC), Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN), Breast Cancer, Chro
- 249 active pipeline program(s) linked via ClinicalTrials.gov.
- 2 US patent(s) indexed to this assignee profile.
- 249 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for AstraZeneca. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Daiichi and AstraZeneca's Enhertu: Early Breast Cancer Breakthrough
- approval
FDA Approval for Datroway: Implications for Breast Cancer Treatment
- deal
AstraZeneca's Breast Cancer Pill and ADAP Deal Insights
- approval
Imfinzi Receives FDA Approval for Bladder Cancer Treatment
- approval
IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer
- approval
FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights
- approval
ASCO26: AstraZeneca's Camizestrant Data Aims to Sway FDA Approval
- approval
ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address
- approval
Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients
- approval
AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer
- approval
FDA Approves AstraZeneca's Imfinzi-BCG Combination for High-Risk NMIBC
- approval
FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
Recent coverage
Truqap gains US approval in PTEN-deficient metastatic prostate cancer
AstraZeneca’s Truqap (capivasertib) has been approved in the US with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer. The move creates a first-in-class targeted option and a new catalyst to watch for BD teams, investors, and analysts.
AstraZeneca expands obesity push as it invests $125M in ultrasound medicine
AstraZeneca’s obesity strategy widened after newly published data supported a sprawling late-stage program for its GLP-1 pill. The company also committed $125 million to ultrasound-aided genetic medicine, signaling continued platform investing.
PMDA approves ENHERTU for HER2-low breast cancer in Japan
PMDA approved ENHERTU for unresectable or metastatic HER2-low breast cancer in Japan, marking a new regulatory catalyst for Daiichi Sankyo and AstraZeneca. The decision expands the drug’s labeled use in a major market and adds another milestone for investors tracking ENHERTU.
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for AstraZeneca.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for AstraZeneca.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is AstraZeneca?
-
Is AstraZeneca publicly traded?
-
What drugs does AstraZeneca develop or market?
-
What are the latest developments for AstraZeneca?
-
What therapeutic areas does AstraZeneca focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
AstraZeneca maintains 249 tracked programs across Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not applicable, healthy volunteers, Chronic kidney disease (CKD) and hypertension., Metastatic Prostate Cancer, Locoregional Hepatocellular Carcinoma (HCC), Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN), Breast Cancer, Chronic Heart Failure, Triple-negative Breast Cancer. Momentum score: 25/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: cambridge GB. Ticker: EBA8A89.
Pipeline programs
D7632C00001 — phase phase_3, status active. Indication: Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.. Next milestone: not disclosed (TBD).
D8991C00001 — phase phase_3, status active. Indication: Advanced Platinum-resistant Epithelial Ovarian Cancer. Next milestone: not disclosed (TBD).
D516FC00001(ADAURA2) — phase phase_3, status active. Indication: Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.. Next milestone: not disclosed (TBD).
D7402C00001 — phase phase_3, status active. Indication: Large B-cell Lymphoma. Next milestone: not disclosed (TBD).
D8534C00001 — phase phase_3, status active. Indication: Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer. Next milestone: not disclosed (TBD).
D8610C00001 — phase phase_3, status active. Indication: Respiratory Syncytial Virus and Human Metapneumovirus. Next milestone: not disclosed (TBD).
D6185C00001 — phase phase_3, status active. Indication: Patients with non-small cell lung cancer (NSCLC).. Next milestone: not disclosed (TBD).
D5241C00006 — phase phase_3, status active. Indication: Chronic obstructive pulmonary disease (COPD). Next milestone: not disclosed (TBD).
D6402C00012 — phase phase_3, status active. Indication: Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death. Next milestone: not disclosed (TBD).
D7310C00001 — phase phase_3, status active. Indication: Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor. Next milestone: not disclosed (TBD).
D8311C00001 — phase phase_3, status active. Indication: Relapsed or Refractory Multiple Myeloma. Next milestone: not disclosed (TBD).
D6900C00003 — phase phase_3, status active. Indication: B7-H4-Selected Advanced/Metastatic Endometrial Cancer.. Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: Truqap gains US approval in PTEN-deficient metastatic prostate cancer (2026-06-13).
Nova coverage: AstraZeneca expands obesity push as it invests $125M in ultrasound medicine (2026-06-11).
Nova coverage: PMDA approves ENHERTU for HER2-low breast cancer in Japan (2026-06-10).
Nova coverage: EMA backs datopotamab deruxtecan, but lung cancer access remains unclear (2026-06-07).
Nova coverage: EMA backs datopotamab deruxtecan for advanced lung cancer (2026-06-07).
Nova coverage: AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint (2026-06-07).
Nova coverage: 5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis (2026-06-06).
Nova coverage: Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target? (2026-06-06).
Registry facts
Registry profile: founded unknown; employees 79242; market cap n/a; revenue n/a; LEI 636700ITSLXVAJVLAY33; CIK n/a.
Company type: pharma; public/private: public. Data quality score: 0.833.
Catalyst calendar
Catalyst: Daiichi and AstraZeneca's Enhertu: Early Breast Cancer Breakthrough — type approval, date 2026-05-19.
Catalyst: FDA Approval for Datroway: Implications for Breast Cancer Treatment — type approval, date 2026-05-23.
Catalyst: AstraZeneca's Breast Cancer Pill and ADAP Deal Insights — type deal, date 2026-05-27.
Catalyst: Imfinzi Receives FDA Approval for Bladder Cancer Treatment — type approval, date 2026-05-30.
Catalyst: IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer — type approval, date 2026-05-30.
Catalyst: FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights — type approval, date 2026-06-01.
Catalyst: ASCO26: AstraZeneca's Camizestrant Data Aims to Sway FDA Approval — type approval, date 2026-06-02.
Catalyst: ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address — type approval, date 2026-06-02.
Catalyst: Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients — type approval, date 2026-06-02.
Catalyst: AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer — type approval, date 2026-06-02.
Competitive peers
Peer: AstraZeneca (overlap score 50.0).
Peer: BEONE MEDICINES AUS (overlap score 50.0).
Peer: Novartis India (overlap score 40.0).
Peer: Sunshine Guojian Pharmaceutical (overlap score 40.0).
Peer: HOFFMANN-LA ROCHE (overlap score 40.0).
Peer: Amgen (overlap score 39.2).
Peer: Eli Lilly and (overlap score 32.4).
Peer: ADC Therapeutics (overlap score 26.0).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.